Advertisement

Reactions Weekly

, Volume 1695, Issue 1, pp 208–208 | Cite as

Idelalisib/rituximab

Various toxicities: 5 case reports
Case report
  • 19 Downloads

Reference

  1. Eyre TA, et al. Idelalisib-rituximab results in considerable toxicity but induces durable clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukemia. Blood 130 (Suppl. 1): abstr. 4068, 2017. Available from: URL: http://www.bloodjournal.org/content/130/Suppl_1/4068?sso-checked=true [abstract] -United Kingdom

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Personalised recommendations